Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.
Kwang Ho In(Brigham and Women's Hospital), Jeffrey M. Drazen(Brigham and Women's Hospital), S W Kim(Harvard University Press), Chandri Yandava(Broad Institute), K Serino(NKT Therapeutics (United States)), David R. Beier(University of Washington), William W. Busse(University of Wisconsin–Madison), Elliot Israel(Brigham and Women's Hospital), Eric S. Silverman(Brigham and Women's Hospital), Tucker Collins(Brigham and Women's Hospital), J Grobholz(Harvard University Press), Ji Murray(Brigham and Women's Hospital), D Tinkleman(Abbott (United Kingdom)), Anthony Pillari(Harvard University Press), Paul Rubin(Abbott (United Kingdom)), George T. De Sanctis(Harvard University Press), D Ledford(Abbott (United Kingdom)), James P. Kemp(Abbott (United Kingdom)), Tim P. Keith(NKT Therapeutics (United States)), Patricia W. Finn(Harvard University Press), Kazuhito Asano(Harvard University Press), Andrew R. Fischer(Harvard University Press), Edward Silverman(Brigham and Women's Hospital), Anthony W. Segal(Soroka Medical Center)
Cited by 336
Related Papers
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
|New England Journal of Medicine|2011|870